Cellect Biotechnology Ltd. announced that it has signed an agreement with the Hadassah Medical Center to conduct clinical trials on cancer patients in Cellect's ongoing Phase I/II study. The study at Hadassah will be conducted under Prof. Polina Stefenski, the Principal Investigator of the site at Hadassah. Furthermore, following the recently announced positive interim results in the Phase I/II clinical trial with the first group of patients treated at the Rambam Medical Center, Cellect received approval from the independent Data and Safety Monitoring Board (DSMB) to escalate ApoGraft™ FasL protein dosage (Cellect's main active ingredient in ApoGraft™) to 25 ng/ml and enroll three additional patients for the clinical trial.